Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.61
−$0.12 · -6.94%
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Previous close
$1.61
−$0.12 · -6.94%
Pre-market
$1.64
+$0.03 · +1.86%
Sep 14, 7:39 AM ET
Regular session · ET · Market data may be delayed.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Day range
Current $1.61
52-week range
Current $1.61
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
23
Expensive
Sentiment
46
Mixed
Risk
73
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Day range
Current $1.61
52-week range
Current $1.61
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 832K USD | — | — | — | — |
| Gross profit | −832K USD | — | — | — | — |
| Research and development | 7.41M USD | 4.5M USD | 2.37M USD | 1.15M USD | 521K USD |
| Selling, general, and administrative | 9.24M USD | 9.23M USD | 6.52M USD | 3.32M USD | 1.06M USD |
| Operating expenses | 15.82M USD | 13.74M USD | 8.89M USD | 4.47M USD | 1.58M USD |
| Interest income | 247K USD | 251K USD | — | — | — |
| Interest expense | 204K USD | 20K USD | 147K USD | 654K USD | 4K USD |
| Depreciation and amortization | 832K USD | 573K USD | 437K USD | 94K USD | — |
| Operating income | −16.65M USD | −13.74M USD | −8.89M USD | −4.47M USD | −1.58M USD |
| Net income | −18.65M USD | −11.16M USD | −16.49M USD | −5.12M USD | −1.58M USD |
Company facts updated Sep 14, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$180
11080.12% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
